Parkinson Archives - UF Innovate

Using Whole-Genome Sequencing To Study Early-Onset Parkinson’s Disease

The Norwegian term for virgin snow, “nysnø”, seemed the appropriate inspiration to name Jennifer Johnston’s company, NysnoBio, as it underscores the pioneering work NysnoBio is doing to tap the potential of Parkin, the protein most often linked to young onset genetic Parkinson’s disease.

UF Joins Global Study Into Parkinson’s Onset and Progression

The University of Florida has been selected to join The Michael J. Fox Foundation’s landmark clinical study, the Parkinson’s Progression Markers Initiative (PPMI), a global project seeking to discover new insights into the onset and progression of Parkinson’s disease by studying people with and without the disease.

UF Neuroscientists Discover Biomarker With Potential To Aid Parkinson’s Diagnosis

University of Florida neuroscientists have developed a new assay, or test, to detect minute amounts of a protein called tyrosine hydroxylase in blood immune cells of Parkinson’s disease patients, a key finding to aid in the development of a blood test to help diagnose and guide treatment for the neurodegenerative disorder.

New Evidence Links Gut Bacteria and Neurodegenerative Conditions

New research published in PLOS Pathogens establishes, for the first time, a link between specific bacteria species and physical manifestations of neurodegenerative diseases.

Is It Time for a New Image of Parkinson’s Disease?

In an article published in the journal JAMA Neurology, Dr. Melissa J Armstrong and Dr. Michael S Okun argue that it is ‘Time for a new image of Parkinson’s disease’ that more accurately reflects the varied experiences of the people with the condition.

AbFero Pharmaceuticals Announces Funding From Cure Parkinson’s for Lead Compound SP-420

AbFero Ltd., a subsidiary of UF startup AbFero Pharmaceuticals, Inc., a privately-held clinical stage pharmaceutical company dedicated to treating diseases of iron overload, announced the award of a grant from Cure Parkinson's for the development of their lead, brain-penetrant iron chelating agent, SP-420, as a disease modifying therapy for Parkinson's disease (PD).

AbFero to Receive € 2M Eurostars Funding for Parkinson’s Disease Therapy

AbFero Ltd., a subsidiary of UF startup AbFero Pharmaceuticals, Inc., a privately-held clinical-stage pharmaceutical company dedicated to treating diseases of iron overload, announced the funding of approximately € 2M from EUREKA Eurostars for the development of iron-chelating compounds including their lead agent, SP-420, as a disease-modifying therapy for Parkinson's disease.

Parkinson